What clinical trials have been run for daridorexant?
Daridorexant is a sleep medicine, and its development has included multiple clinical trials focused on treating insomnia. Trial programs generally evaluate how well daridorexant reduces “time to sleep onset” and improves sleep outcomes (and how tolerable it is).
What phases were used in daridorexant’s clinical development?
Clinical programs for drugs like daridorexant typically progress through:
- Phase 1 studies to understand safety and pharmacology in volunteers.
- Phase 2 studies to test dosing and early efficacy in people with insomnia.
- Phase 3 trials to confirm efficacy and safety at selected doses in larger patient groups.
Specific phase-by-phase trial names, dates, and outcome details depend on the individual study identifiers (for example, NCT numbers), which are not included in the information provided here.
What endpoints do insomnia trials of daridorexant typically measure?
Insomnia trials commonly track endpoints such as:
- Sleep onset latency (how quickly a person falls asleep)
- Total sleep time or wake after sleep onset
- Sleep efficiency
- Patient-reported sleep questionnaires
- Safety and tolerability, including next-day impairment-related adverse effects
How do researchers evaluate safety and next-day effects in daridorexant trials?
Insomnia drugs are evaluated for:
- Sedation-related adverse events
- Balance or falls risk signals
- Cognitive effects and next-day drowsiness measures
- Overall discontinuation rates and dose-related tolerability
Where can I find trial details (NCT numbers, results, and publications)?
To get the exact clinical-trial records (trial IDs, inclusion criteria, primary endpoints, and reported results) for daridorexant, you typically need to look up the specific studies in clinical trial registries and peer-reviewed publications. The most direct way depends on whether you want:
- all registered daridorexant trials,
- only Phase 3 pivotal trials,
- or trials in specific populations (elderly, comorbid insomnia/medication use, etc.).
If you want, tell me which you’re looking for
If you share one of the following, I can narrow the trial set and focus on what you care about:
- Do you mean Phase 3/pivotal trials, or any phase?
- Are you looking for efficacy results, safety results, or both?
- Any specific population (elderly, severe insomnia, comorbidities)?
- Do you have an NCT number or publication title?
Sources
None provided in the question text.